Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cue Biopharma, Inc. (CUE) SEC filings page provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company (Commission File Number 001-38327), Cue Biopharma uses SEC reports to communicate financial results, material agreements, leadership changes and other significant corporate events.
Investors researching CUE stock can review Form 10-K annual reports and Form 10-Q quarterly reports for detailed information on collaboration revenue, research and development spending, general and administrative expenses, cash and marketable securities, and risk factors related to the development of its Immuno-STAT® platform and pipeline candidates such as CUE-101, CUE-102, CUE-401 and CUE-501.
Form 8-K current reports are particularly relevant for Cue Biopharma, as they document material events including collaboration and license agreements, public offerings under its Form S-3 shelf registration statement, changes in executive leadership, facility lease amendments and key licensing transactions like the collaboration with ImmunoScape for the CUE-100 series. These filings often reference press releases furnished as exhibits, providing additional context on clinical and business developments.
This page also helps users locate information related to equity compensation and executive arrangements, which are described in employment agreements and separation agreements disclosed in 8-K filings. While Cue Biopharma’s insider transactions would appear in Form 4 filings submitted by individual officers and directors, aggregating these documents alongside periodic reports offers a fuller picture of governance and ownership activity.
Stock Titan enhances access to Cue Biopharma’s SEC filings with AI-powered summaries that explain key points from lengthy documents, highlight notable changes from prior periods and surface items that may be important to shareholders. Real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K and related forms are available promptly, helping users navigate the regulatory record behind CUE stock.
Cue Biopharma reported third‑quarter results, highlighting lower collaboration revenue and continued operating losses, alongside a new collaboration that adds near‑term cash. Collaboration revenue was
Liquidity remained tight with cash, cash equivalents and marketable securities of
Cue Biopharma (CUE) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The release is furnished as Exhibit 99.1.
The company notes that the information in this report, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth by specific reference.
Cue Biopharma (CUE) announced a Collaboration and License Agreement with ImmunoScape Pte. Ltd. (IMSCP), following IMSCP’s exercise of an option on
The structure grants IMSCP a co-exclusive development license for five years or longer (while a specified number of CUE‑100 Series molecules remain under active development), with Cue retaining non‑exclusive research rights to support other programs. IMSCP also receives an exclusive commercial license for any CUE‑100 Series molecule it advances to IND‑enabling studies during the co‑exclusive period.
Cue received
Cue Biopharma director and CEO Usman Azam was granted a stock option on 09/29/2025 to purchase 1,875,000 shares of common stock at an exercise price of $0.72 per share. The option was reported on Form 4 filed 10/02/2025 and becomes exercisable in 48 monthly installments beginning 09/29/2026, with an expiration date of 09/28/2035. After the grant, Azam beneficially owns 1,875,000 underlying shares directly. The filing was signed by an attorney-in-fact on Azam's behalf.
Usman Azam filed a Form 3 reporting his relationship to Cue Biopharma, Inc. (CUE) as both a director and the Chief Executive Officer. The form shows the date of event as 09/29/2025 and states that no securities are beneficially owned by the reporting person as of the filing. The filing was executed by an attorney-in-fact on 10/02/2025 and includes an exhibit: Exhibit 24.1 - Power of Attorney.
Cue Biopharma is making a planned leadership transition, appointing Usman Azam as President and Chief Executive Officer and a director effective September 29, 2025, as longtime CEO Daniel R. Passeri retires from the role and the board but continues as a strategic advisor.
Under his employment agreement, Dr. Azam will receive a $620,000 annual base salary, a target bonus of up to 50% of base salary, and stock options for 1,875,000 time-based shares plus 375,000 performance-based shares that vest in full if a specified financing milestone is achieved. If he is terminated without cause or resigns for good reason, he is eligible for cash severance equal to 12 months of base salary plus a prorated target bonus and up to 12 months of COBRA premium payments.
Through a separation agreement, Mr. Passeri will receive a lump-sum cash payment of $838,750, up to 18 months of COBRA premiums, and a 12‑month acceleration of vesting and extended exercisability of his existing equity awards. An advisor agreement running to March 30, 2026 grants him an additional option for 375,000 shares that vests if the same financing milestone is met while his existing awards continue to vest during his advisory term.
Cue Biopharma filed a Form S-8 to register securities under its 2025 Stock Incentive Plan, enabling the company to grant equity awards to employees, directors and other service providers. The registration statement incorporates by reference the company’s annual report for the fiscal year ended December 31, 2024, its quarterly reports for the quarters ended March 31, 2025 and June 30, 2025, and a set of current reports and other SEC filings, and it updates the company’s description of its common stock via Exhibit 4.2 to the 2024 annual report.
The filing omits plan narrative from Part I because those documents were provided separately to plan participants under Rule 428; exhibits included or incorporated by reference cover the 2025 Stock Incentive Plan, the amended and restated certificate of incorporation and bylaws, legal opinion and auditor consents, a power of attorney and the calculation of filing fee tables. The statement also summarizes the company’s indemnification framework for directors and officers, including indemnification agreements and directors’ and officers’ liability insurance.
Cue Biopharma reported continued clinical-stage operating losses while taking steps to bolster liquidity through financing and partnerships. The company held $27.5 million of cash and cash equivalents as of June 30, 2025 and reported a net loss of $20.7 million for the six months ended June 30, 2025 (net loss of $8.48 million for the quarter). Accumulated deficit was $362.6 million and weighted average shares outstanding increased to 84.86 million for the six-month period.
The company raised capital through a 2025 public offering that generated $18.0 million net proceeds, modest ATM proceeds during the period, and received a $10.1 million upfront payment from a collaboration and license agreement with Boehringer Ingelheim (BI) that also includes up to approximately $345 million in potential milestones and royalties. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes all Term Loans are due December 1, 2025.
Cue Biopharma, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is included as Exhibit 99.1 to this Current Report and the company states that the information is being "furnished" rather than "filed," so it is not subject to the liability provisions of Section 18 of the Exchange Act and is not incorporated by reference into other filings except by specific reference. The registrant’s common stock trades on the Nasdaq Capital Market under the symbol CUE.